Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 1/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21198979 | 0.80 | CYP17A1 (0.43) | SOS1L3MBTL1PKMCYP17A1 | |
| SCHEMBL21199105 | 0.77 | SOS1 (0.39) | SOS1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL2966227 | 0.76 | ADA (0.48) | ADACYP17A1 | |
| SCHEMBL2983271 | 0.76 | ADA (0.48) | ADACYP17A1 | |
| SCHEMBL6385922 | 0.76 | SOS1 (0.41) | SOS1L3MBTL1PKM | |
| SCHEMBL18516673 | 0.74 | ADA (0.46) | ADAL3MBTL1PKMTAAR1 | |
| SCHEMBL14004028 | 0.74 | PKM (0.48) | SOS1L3MBTL1PKMTAAR1 | |
| SCHEMBL31478673 | 0.69 | SOS1 (0.35) | SOS1L3MBTL1PKMHTR2AHTR2C | |
| SCHEMBL17632850 | 0.68 | HTR2A (0.58) | SOS1L3MBTL1HTR2AHTR2CHTR2B | |
| SCHEMBL21199185 | 0.68 | SOS1 (0.58) | SOS1L3MBTL1PKMTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7781435-B2 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC (US) | 2010-08-24 | — | — | US | disclosed |
| CN-101282941-A | Imidazole compounds for the treatment of neurological disorders | PFIZER (US) | 2008-10-08 | — | — | CN | disclosed |
| EP-1940802-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | Pfizer Products Inc. (US) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007034326-A2 | IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | PFIZER PRODUCTS INC. (US) | 2007-03-29 | — | — | WO | disclosed |
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | PFIZER INC | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066613-A1 | Imidazole compounds for the treatment of neurological disorders | APP, PSEN1, BACE1 | ADA 2029/4885SOS1 4782/4885L3MBTL1 1649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.